Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRVL

Prevail Therapeutics (PRVL) Stock Price, News & Analysis

Prevail Therapeutics logo

About Prevail Therapeutics Stock (NASDAQ:PRVL)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$23.00
$23.00
50-Day Range
$22.91
$23.20
52-Week Range
$9.02
$23.35
Volume
N/A
Average Volume
955,800 shs
Market Capitalization
$787.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Remove Ads
Receive PRVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRVL Stock News Headlines

DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
See More Headlines

PRVL Stock Analysis - Frequently Asked Questions

Prevail Therapeutics Inc. (NASDAQ:PRVL) released its quarterly earnings data on Friday, November, 13th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.09.

Prevail Therapeutics (PRVL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prevail Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Alector (ALEC), Advanced Micro Devices (AMD), Atreca (BCEL) and Homology Medicines (FIXX).

Company Calendar

Last Earnings
11/13/2020
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVL
CIK
N/A
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-63,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.85 per share
Price / Book
4.74

Miscellaneous

Free Float
N/A
Market Cap
$787.66 million
Optionable
Not Optionable
Beta
1.59
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PRVL) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners